Oxidative damage to human lens epithelial cells in culture: Estrogen protection of mitochondrial potential, ATP, and cell viability

Investigative Ophthalmology and Visual Science

Volumn 44, Issue 5, 2003, Pages 2067-2075

  Wang, Xiaofei ^a,b   Simpkins, James W ^a   Dykens, James A ^c   Cammarata, Patrick R ^a  

^a UNIVERSITY OF NORTH TEXAS HEALTH SCIENCE CENTER   (United States)

^b UNIVERSITY OF FLORIDA HEALTH   (United States)

^c Migenix Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

17ALPHA ESTRADIOL; ACETOACETIC ACID DERIVATIVE; ADENOSINE TRIPHOSPHATE; CALCEIN; ESTRADIOL; ESTROGEN; HYDROGEN PEROXIDE; REACTIVE OXYGEN METABOLITE;

ARTICLE; CELL CULTURE; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; EPITHELIUM CELL; HUMAN; HUMAN CELL; LENS EPITHELIUM; MITOCHONDRION; OXIDATIVE STRESS; PRIORITY JOURNAL;

ADENOSINE TRIPHOSPHATE; CELL CULTURE TECHNIQUES; CELL LINE; CELL SURVIVAL; CYTOPROTECTION; DOSE-RESPONSE RELATIONSHIP, DRUG; EPITHELIAL CELLS; ESTRADIOL; ESTROGEN ANTAGONISTS; FLUORESCEINS; HUMANS; HYDROGEN PEROXIDE; LENS, CRYSTALLINE; MEMBRANE POTENTIALS; MITOCHONDRIA; OXIDATIVE STRESS; REACTIVE OXYGEN SPECIES;

EID: 0037407577     PISSN: 01460404     EISSN: None     Source Type: Journal    
DOI: 10.1167/iovs.02-0841     Document Type: Article

References (55)

1. Steinberg EP, Javitt JC, Sharkey PD, et al. The content and cost of cataract surgery. Arch Ophthalmol. 1993;111:1041-1049.
2. Shibata T, Sasaki K, Katoh N, Hatano T. Population-based case-control study of cortical cataract in the Noto area, Japan. Dev Ophthalmol. 1994;26:25-33.
3. McCarty CA, Mukesh BN, Fu CL, Taylor HR. The epidemiology of cataract in Australia. Am J Ophthalmol. 1999;128:446-465.
4. Livingston PM, Guest CS, Stanislavsky Y, et al. A population-based estimate of cataract prevalence: the Melbourne Visual Impairment Project experience. Dev Ophthalmol. 1994;26:1-6.
5. Klein BE, Klein R, Linton KL. Prevalence of age-related lens opacities in a population. The Beaver Dam Eye Study. Ophthalmology. 1992;99:546-552
6. Klein BE, Klein R, Lee KE. Incidence of age-related cataract: the Beaver Dam Eye Study. Arch Ophthalmol. 1998;116:219-225.
7. Freeman EE, Munoz B, Schein OD, West SK. Hormone replacement therapy and lens opacities: the Salisbury Eye Evaluation project. Arch Ophthalmol. 2001;119:1687-1692.
8. Cumming RG, Mitchell P. Hormone replacement therapy, reproductive factors, and cataract. The Blue Mountains Eye Study. Am J Epidemiol. 1997;145:242-249.
9. Harding JJ. Estrogens and cataract. Arch Ophthalmol. 1994;112:1511.
10. Klein BE, Klein R, Ritter LL. Is there evidence of an estrogen effect on age-related lens opacities? The Beaver Dam Eye Study. Arch Ophthalmol. 1994;112:85-91.
11. Younan C, Mitchell P, Cumming RG, Panchapakesan J, Rochtchina E, Hales AM. Hormone replacement therapy, reproductive factors, and the incidence of cataract and cataract surgery: the Blue Mountains Eye Study. Am J Epidemiol. 2002;155:997-1006.
12. Weintraub JM, Taylor A, Jacques P, et al. Postmenopausal hormone use and lens opacities. Ophthalmic Epidemiol. 2002;9:179-190.
13. Hales AM, Chamberlain CG, Murphy CR, McAvoy JW. Estrogen protects lenses against cataract induced by transforming growth factor-beta (TGFbeta). J Exp Med. 1997;185:273-280.
14. Bigsby RM, Cardenas H, Caperell-Grant A, Grubbs CJ. Protective effects of estrogen in a rat model of age-related cataracts. Proc Natl Acad Sci USA. 1999;96:9328-9332.
15. Green PS, Gridley KE, Simpkins JW. Estradiol protects against beta-amyloid (25-35)-induced toxicity in SK-N-SH human neuroblastoma cells. Neurosci Lett. 1996;218:165-168.
16. Green PS, Perez EJ, Calloway T, Simpkins JW. Estradiol attenuation of beta-amyloid-induced toxicity: a comparison of MTT and calcein AM assays. J Neurocytol. 2000;29:419-423.
17. Wang J, Green PS, Simpkins JW. Estradiol protects against ATP depletion, mitochondrial membrane potential decline and the generation of reactive oxygen species induced by 3-nitroproprionic acid in SK-N-SH human neuroblastoma cells. J Neurochem. 2001;77:8048-8011.
18. Mukai K, Daifuku K, Yokoyama S, Nakano M. Stopped flow investigation of antioxidant activity of estrogens in solution. Biochem Biophys Acta. 1990;1035:348-352.
19. Rifici VA, Khachadurian AK. The inhibition of low-density lipoprotein oxidation by 17-beta estradiol. Metabolism. 1992;41:1110-1114.
20. Sack MN, Rader DJ, Cannon RO III. Oestrogen and inhibition of oxidation of low-density lipoproteins in postmenopausal women. Lancet. 1994;343:269-270.
21. Green PS, Gordon K, Simpkins JW. Phenolic A ring requirement for the neuroprotective effects of steroids. J Steroid Biochem Mol Biol. 1997;63:229-235.
22. Gridley KE, Green PS, Simpkins JW. A novel, synergistic interaction between 17 beta-estradiol and glutathione in the protection of neurons against beta-amyloid 25-35-induced toxicity in vitro. Mol Pharmacol. 1998;54:874-880.
23. Behl C, Skutella T, Lezoualc'h F, Post A, Widmann M, Newton CJ, Holsboer, F. Neuroprotection against oxidative stress by estrogens: structure-activity relationship. Mol Pharmacol. 1997;51:535-541.
24. Spector A, Scotto R, Weissbach H, Brot N. Lens methionine sulfoxide reductase. Biochem Biophys Res Commun. 1982;108:429-434.
25. Bhuyan KC, Bhuyan DK, Podos SM. Lipid peroxidation in cataract of the human. Life Sci. 1986;38:1463-1471.
26. Ramachandran S, Morris SM, Devamanoharan P, Henein M, Varma SD. Radio-isotopic determination of hydrogen peroxide in aqueous humor and urine. Exp Eye Res. 1991;53:503-506.
27. Spector A. Oxidative stress-induced cataract: mechanism of action. FASEB J 1995;9:1173-1182.
28. Green PS, Yang SH, Nilsson KR, Kumar AS, Covey DF, Simpkins JW. The nonfeminizing enantiomer of 17beta-estradiol exerts protective effects in neuronal cultures and a rat model of cerebral ischemia. Endocrinology. 2001;142:400-406.
29. Andley UP, Rhim JS, Chylack LT Jr, Fleming TP. Propagation and immortalization of human lens epithelial cells in culture. Invest Ophthalmol Vis Sci. 1994;35:3094-3102.
30. Halliwell B, Gutteridge JMC. Free Radicals in Biology and Medicine. 3rd ed. Oxford, UK: Oxford University Press; 1999:381-385.
31. Garewal HS, Ahmann FR, Schifman RB, Celniker A. ATP assay: ability to distinguish cytostatic from cytocidal anticancer drug effects. J Natl Cancer Inst. 1986;77:1039-1045.
32. Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem. 1976;72:248-254.
33. Dykens, JA, Stout AK. Fluorescent dyes and assessment of mitochondrial membrane potential in FRET modes. Methods Cell Biol. 2001;65:285-309.
34. Dykens JA, Fleck B, Ghosh S, Lewis M, Velicelebi G, Ward M. A novel FRET-based assay of mitochondrial membrane potential in situ. Mitochondrion. 2002;1:461-473.
35. Korenman SG. Comparative binding affinity of estrogens and its relation to estrogenic potency. Steroids. 1969;13:163-177.
36. Clark JH, Williams M, Upchurch S, Eriksson H, Helton E, Markaverich BM. Effects of estradiol-17 alpha on nuclear occupancy of the estrogen receptor, stimulation of nuclear type II sites and uterine growth. J Steroid Biochem. 1982;16:323-328.
37. Lubahn DB, McCarty KS Jr, McCarty KS Sr. Electrophoretic characterization of purified bovine, porcine, murine, rat, and human uterine estrogen receptors. J Biol Chem. 1985;260:2515-2526.
38. Dykens JA. Mitochondrial radical production and mechanisms of oxidative excitotoxicity. In: Davies KJA, Ursini F, eds. The Oxygen Paradox. Cleup Press, University of Padova; 1995:453-467.
39. Dykens JA. Mitochondrial free radical production and the etiology of neurodegenerative disease. In: Beal MF, Bodis-Wollner I, Howell N, eds. Neurodegenerative Diseases: Mitochondria and Free Radicals in Pathogenesis. New York: John Wiley & Sons; 1997;29-55.
40. Prokai L, Oon SM, Prokai-Tatrai K, Abboud KA, Simpkins JW. Synthesis and biological evaluation of 17 b-alkoxyestra-1, 3, 5(10)-trienes: potential neuroprotectants against oxidative stress. J Med Chem. 2001;44:110-114.
41. Gridley KE, Green PS, Simpkins JW. Low concentrations of estradiol reduce beta-amyloid (25-35)-induced toxicity, lipid peroxidation and glucose utilization in human SK-N-SH neuroblastoma cells. Brain Res. 1997;778:158-165.
42. Hyslop PA, Hinshaw DB, Halsey WA Jr, et al. Mechanisms of oxidant-mediated cell injury: the glycolytic and mitochondrial pathways of ADP phosphorylation are major intracellular targets inactivated by hydrogen peroxide. J Biol Chem. 1988;263:1665-1675.
43. +: implications for neurodegeneration. J. Neurochem. 1994;63:584-591.
44. Murphy AN, Fiskum G, Beal MF. Mitochondria in neurodegeneration: bioenergetic function in cell life and death. J Cereb Blood Flow Metab. 1999;19:231-245.
45. Dykens JA. Free radicals and mitochondrial dysfunction in excitotoxicity and neurodegenerative diseases. Koliatos VE, Ratan VV. Cell Death and Diseases of the Nervous System. Clifton, NJ: Humana Press; 1999;45-68.
46. Simpkins JW, Singh M, Bishop J. The potential role for estrogen replacement therapy in the treatment of the cognitive decline and neurodegeneration associated with Alzheimer's disease. Neurobiol Aging. 1994;15:S195-S197.
47. Green PS, Simpkins JW. Role of estrogens and estrogen-like nonfeminizing compounds in the prevention and treatment of Alzheimer's disease. Ann NY Acad Sci. 2000;924:93-98.
48. McEwen BS. Estrogens effects on the brain: multiple sites and molecular mechanisms. J Appl Physiol. 2001;91:2785-2801.
49. Wise PM, Dubal DB, Wilson ME, Rau SW, Bottner M. Neuroprotective effects of estrogen-new insights into mechanisms of action. Endocrinology. 2001;142:969-973.
50. Brinton RD. Cellular and molecular mechanisms of estrogen regulation of memory function and neuroprotection against Alzheimer's disease: recent insights and remaining challenges. Learn Mem. 2001;8:121-133.
51. Simpkins JW, Green PS, Gridley KE. Fundamental role for estrogens in cognition and neuroprotection. Brioni JD, Decker MW. Pharmacological Treatment of Alzheimer's Disease. New York: Wiley-Liss; 1997;503-524.
52. Stout AK, Raphael HM, Kanterewicz BI, Klann E, Reynolds IJ. Glutamate-induced neuron death requires mitochondrial calcium uptake. Nat Neurosci. 1998;1:366-373.
53. Han HJ, Park SH, Park HJ, et al. Effect of various oestrogens on cell injury and alteration of apical transporters induced by tert-butyl hydroperoxide in renal proximal tubule cells. Clin Exp Pharmacol Physiol. 2002;29:60-67.
54. Reddan J, Sevilla M, Giblin F, Padgaonkar V, Dziedzic D, Leverenz V. Tempol and deferoxamine protect cultured rabbit lens epithelial cells from H2O2 insult: insight into the mechanism of H2O2-induced injury. Lens Eye Toxic Res. 1992;9:385-393.
55. Davis VL, Chan CC, Schoen TJ, Couse JF, Chader GJ, Korach KS. An estrogen receptor repressor induces cataract formation in transgenic mice. Proc Natl Acad Sci USA. 2002;99:9427-9732.